You are subscribed to the FormularyWatch.

Formulary

eNewsletter Subscribe

November 17, 2014

Web Version  | Share with a colleague

Facebook Like Twitter Tweet

Today's Headlines

Compounding may not be best option during saline shortage

The saline solution shortage is ongoing and safety concerns make it prohibitive for hospitals to compound their own solutions, according to an American Society of Health-System Pharmacists (ASHP) quality executive. » 3 tips for managing the saline shortage

Popular statin leads list of most-prescribed drugs

Here are the 10 top-selling drugs in order of number of prescriptions. » Read what drugs top the list by total sales

Continuing Education

MTM essentials for weight management

This month's CE activity is part of a year-long CPE series, Medication Therapy Management Considerations for Adult Patients with Cardiovascular Disease. From February 2014 through January 2015, pharmacists can earn up to 24 hours of CPE credit with 12 monthly knowledge-based activities from the University of Connecticut School of Pharmacy and Drug Topics.

The goal of this month's activity is to educate pharmacists about the prevalence, health consequences, and nonpharmacologic and pharmacologic treatment options for obesity, with a focus on the recommendations made in the 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults.

To read and print the article with TEST QUESTIONS, click here. To proceed to the online exam and earn up to 2 CPE credits, click here to log in with the session code 14DT12-FKX42.


Announcement: Our CE activities have moved to a new learning management system to better serve you. The login to the Online CE Center is https://web2.uconn.edu/pharmacyce/login.php. All current user registration information has been uploaded for your convenience. Current users do not need to register. To review your registration page to ensure the data is up to date or to register, go to https://web2.uconn.edu/pharmacyce/program_register.php. For a full list of courses, go to http://pharmacy.uconn.edu/academics/ce/drug-topics-and-uconn-ce/

EDITOR'S PICK

FDA approves combo pill for adults with type 2 diabetes

FDA has approved once-daily dapagliflozin and metformin hydrochloride extended-release (Xigduo XR, AstraZeneca) for the treatment of adults with type 2 diabetes. Xigduo XR is indicated as an adjunct therapy to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both dapagliflozin and metformin is appropriate. » Read more about this drug's approval

 

RELATED ARTICLES

[BLOG]: Effective collaboration can help to mitigate drug shortages

Cigna uses predictive risk modeling to identify patients likely to benefit from aggressive LDL-C lowering statin treatment

RESOURCES

Latest Clinical News

Powered by Modern Medicine Advanstar Medical Communications Group